Clinical Trials Logo

Conjunctivitis clinical trials

View clinical trials related to Conjunctivitis.

Filter by:

NCT ID: NCT00775658 Completed - Allergic Rhinitis Clinical Trials

Olopatadine Eye Drops and Allergy Skin Testing

Start date: January 2008
Phase: N/A
Study type: Interventional

Use of olopatadine ophthalmic solution (eye drops) will decrease allergy skin test reactivity.

NCT ID: NCT00770315 Completed - Rhinitis, Allergic Clinical Trials

Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234)

Start date: September 2009
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy and safety of ragweed sublingual tablet (SCH 39641/MK-3641/Amb a 1-U) compared with placebo in participants with ragweed-induced rhinoconjunctivitis over a one-year period. It is expected that ragweed allergic participants on one of the active arms of the trial will have decreased allergic rhinoconjunctivitis symptoms and require less allergy rescue medications during ragweed pollen season.

NCT ID: NCT00770133 Completed - Clinical trials for Allergic Conjunctivitis

Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis.

Start date: February 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to establish the safety and efficacy of ketotifen/naphazoline ophthalmic solution compared to vehicle and its individual components in alleviating the signs and symptoms of conjunctival allergen challenge (CAC)-induced allergic conjunctivitis.

NCT ID: NCT00769886 Completed - Clinical trials for Allergic Conjunctivitis

Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.

Start date: October 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to establish the safety and efficacy of ketotifen/naphazoline ophthalmic solution compared to vehicle and its individual components in alleviating the signs and symptoms of conjunctival allergen challenge (CAC)-induced allergic conjunctivitis.

NCT ID: NCT00759148 Completed - Clinical trials for Bacterial Conjunctivitis

Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial Conjunctivitis

Start date: October 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of Moxifloxacin AF Ophthalmic Solution compared to Moxifloxacin AF Vehicle in the treatment of bacterial conjunctivitis in patients one month of age or older.

NCT ID: NCT00732446 Completed - Blepharitis Clinical Trials

Safety/Efficacy of Antibiotic Steroid Combination in Treatment of Blepharitis and/or Keratitis and/or Conjunctivitis

BRA-07-02
Start date: August 2008
Phase: Phase 3
Study type: Interventional

Safety and efficacy of antibiotic steroid combination compared with individual administration in the treatment of bacterial ocular inflammation and infection (blepharitis and/or keratitis and/or conjunctivitis).

NCT ID: NCT00718744 Completed - Clinical trials for Rhinitis, Allergic, Seasonal

Standardization of Chortoglyphus Arcuatus Allergenic Extract. Determination of Biological Activity in HEP Units

Start date: June 2008
Phase: Phase 2
Study type: Interventional

The main purpose of the trial is to prove the therapeutic value of the product and enable an effective and safe dosage schedule to be recommended

NCT ID: NCT00705159 Completed - Conjunctivitis Clinical Trials

Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis

Start date: June 2008
Phase: Phase 4
Study type: Interventional

The objective of this study is to evaluate the safety and effectiveness of Zylet in comparison with Lotemax, Tobramycin and the vehicle of Zylet for the treatment of blepharoconjunctivitis in pediatric subjects.

NCT ID: NCT00689078 Completed - Clinical trials for Allergic Conjunctivitis

Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model

Start date: May 2008
Phase: Phase 4
Study type: Interventional

To evaluate the efficacy of prednisolone acetate 1% ophthalmic suspension as compared to prednisolone acetate 0.12% ophthalmic suspension, loteprednol etabonate 0.2% ophthalmic suspension, and placebo (Tears Naturale® II) in the prevention of the signs and symptoms of allergic conjunctivitis. Comparisons will be made following 1 week of twice daily (BID) dosing and 1 week of four times daily (QID) dosing.